List view / Grid view
9 September 2015 | By Victoria White
For the primary endpoint of the study, the risk of dying on Relvar/Breo Ellipta 100/25mcg was 12.2% lower than on placebo over the study period, which was not statistically significant...
9 September 2015 | By Victoria White
Raxone is the first approved treatment for Leber’s Hereditary Optic Neuropathy, and for a mitochondrial disease, in the EU...
9 September 2015 | By Victoria White
AstraZeneca and The University of Manchester are teaming up to harness clinical bioinformatics to deliver personalised healthcare for cancer patients...
8 September 2015 | By HORIBA Scientific
HORIBA Scientific, global leader in Raman spectroscopy solutions, announces an innovative solution that addresses the challenges of TERS imaging...
8 September 2015 | By Victoria White
Biogen's Phase 3 programme includes two global studies designed to evaluate the efficacy and safety of aducanumab in slowing cognitive impairment and the progression of disability in people with early Alzheimer’s disease...
8 September 2015 | By Victoria White
Tuzistra XR is the only codeine-based extended-release cough cold syrup available to patients and physicians in the United States...
8 September 2015 | By Victoria White
This increase will be driven primarily by the introduction of novel immune-checkpoint inhibitors, such as Opdivo and Keytruda, says GBI Research...
8 September 2015 | By Victoria White
The trial will measure immune responses following administration of Pennvax-GP in four groups of healthy subjects receiving the vaccine with and without an immune activator (IL-12)...
8 September 2015 | By Tecan
Phenomenex, Inc. and the Tecan Group (SIX Swiss Exchange: TECN) today announced a collaboration to co-market automated solid phase extraction (SPE) sample preparation solutions...
8 September 2015 | By Victoria White
SNF472 is an experimental drug for the treatment of cardiovascular diseases linked to calcification in patients with end stage renal disease...
8 September 2015 | By Victoria White
In two studies, Opdivo showed an estimated 18 month overall survival rate of 27% to 28% in patients with previously treated squamous non-small cell lung cancer (NSCLC)...
7 September 2015 | By Victoria White
The MHRA has said it is now seeing greater appreciation among pharmaceutical sector companies of the skills required for the essential Responsible Person role...
7 September 2015 | By Cherwell Laboratories
Company maintains focus on quality to meet customer expectations...
7 September 2015 | By Victoria White
The announcement follows a review that found that CDF spending would rise to around £410 million for this year - an over-spend of £70m from the budget set in April 2015...
7 September 2015 | By Victoria White
NICE has recommended that pembrolizumab is made available on the NHS as a treatment for some patients with advanced melanoma which is either unresectable or metastatic...
